- IGC purchased exclusive rights to USF patent focused on preventing amyloid-beta plaques from aggregating on neurons
- Company plans to pursue clinical trials related to this patent on path to FDA approval
- In 2017, direct costs associated with Alzheimer’s and other dementias will total an estimated $259 billion, according to the Alzheimer’s Association
If you are an investor, there have been significant developments over the past year that you should be tracking. These include remarkable, if preliminary, results regarding the effect of THC on amyloid-beta plaques, the plaques on neurons associated with Alzheimer’s disease, as well as a critical link between the related technology and India Globalization Capital (NYSE MKT: IGC). This information was summarized in an article first published on Benzinga (http://dtn.fm/MS9cb) and recently adapted for HIGH TIMES (http://dtn.fm/w5DS9), titled “Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work”.
Details from these articles include:
- A paper published by the Salk Institute has validated a study by the University of South Florida, indicating that low doses of THC (one of the main chemical compounds present in marijuana) break up amyloid-beta plaques on neurons.
- The prestigious journal Nature then published a paper showing that “cognitive function was restored in old mice who were given low doses of THC.”
- After discovering that THC in low doses binds to amyloid-beta plaques, preventing them from aggregating on neurons, the University of South Florida filed a patent for that mechanism.
- Following intensive negotiations, India Globalization Capital, a diverse Maryland-headquartered company now focused on the development of cannabis-based therapies, bought the exclusive rights to that U.S. patent filing.
In the articles, Ram Mukunda, IGC CEO, states, “In Alzheimer’s Disease, beta-amyloid aggregates into a plaque-like substance that builds around the neurons and disrupts communication between them. So of course, if low-doses of THC can break up those plaques and prevent them from forming in the first place, it’s a huge breakthrough.”
He further explains that “What IGC is going to do with this patent is take it to clinical trials. We have productized it, and there is more than sufficient evidence. So, now we are now talking to several different places to see where we can begin clinical testing on the path to FDA approval.”
“[W]e are the only cannabis-based pharmaceutical company working on Alzheimer’s,” Mukunda concluded.
For more information, please visit the company’s website at www.IGCInc.us
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com